August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...

Background: Paliperidone palmitate is a long-acting injectable atypical antipsychotic for the acute and maintenance treatment of adults with schizophrenia. The recommended initiation dosing regimen is ...

If approved, paliperidone palmitate 3-monthly injection will be the first once-every-three-months treatment for schizophrenia in the UK Janssen UK announced today that the Committee for Medicinal ...

PRINCETON, N.J., April 6, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI ® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in ...

Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study published ...

The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...

Every-6-month dosing of the long-acting injectable paliperidone palmitate (Invega Hafyera) for schizophrenia was effective and safe up to 3 years, researchers reported during a poster presentation at ...

Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data Additional ...

INVEGA SUSTENNA® (paliperidone palmitate) was approved by the U.S. FDA in July 2009 as the first once-monthly atypical long-acting injection to treat schizophrenia and is now approved in more than 80 ...

PRINCETON, N.J., July 28, 2024 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today ...